Imperial College London
Portrait Picture

Professor Chris Gale

Faculty of Medicine, School of Public Health

Professor of Neonatal Medicine
 
 
 
//

Contact

 

+44 (0)20 3315 3519christopher.gale Website

 
 
//

Location

 

Academic Neonatal Medicine, H4.4,Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Duhig:2021:10.1016/j.preghy.2020.10.005,
author = {Duhig, KE and Myers, JE and Gale, C and Girling, JC and Harding, K and Sharp, A and simpson, NAB and Tuffnell, D and Seed, PT and Shennan, AH and Chappell, LC},
doi = {10.1016/j.preghy.2020.10.005},
journal = {Pregnancy Hypertension},
pages = {41--47},
title = {Placental growth factor measurements in the assessment of women with suspected preeclampsia: a stratified analysis of the PARROT trial},
url = {http://dx.doi.org/10.1016/j.preghy.2020.10.005},
volume = {23},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectivePlacental growth factor testing decreases time to recognition of preeclampsia and may reduce severe maternal adverse outcomes. This analysis aims to describe the clinical phenotype of women by PlGF concentration, and to determine the mechanism(s) underpinning the reduction in severe maternal adverse outcomes in the PARROT trial, in order to inform how PlGF testing may be optimally used within clinical management algorithms.Study designThis was a planned secondary analysis from the PARROT trial that compared revealed PlGF testing and management guidance with usual care in the assessment of women with suspected preterm preeclampsia.Main outcome measuresMaternal and perinatal outcomes following stratification of women by trial group, and measured PlGF concentration.Results1006 women were included. PlGF < 100 pg/ml identified women with more marked hypertension, increased adverse maternal outcomes and preterm delivery rates, and higher rates of small for gestational age infants. There was a reduction in adverse maternal outcomes in women whose results were revealed when PlGF levels were 12–100 pg/ml compared to usual care (3.8% vs 6.9%; aOR 0.15(95% CI 0.03–0.92). There was no significant difference in gestation at delivery between concealed or revealed groups in any PlGF categories.ConclusionLow PlGF concentrations are associated with severe preeclampsia. The reduction in severe adverse maternal outcomes may be mediated through quicker diagnosis and intensive surveillance, as recommended by the management algorithm for those at increased risk. PlGF is particularly beneficial in those who test 12–100 pg/ml, as these may be women with silent multi-organ disease who otherwise may go undetected.
AU  - Duhig,KE
AU  - Myers,JE
AU  - Gale,C
AU  - Girling,JC
AU  - Harding,K
AU  - Sharp,A
AU  - simpson,NAB
AU  - Tuffnell,D
AU  - Seed,PT
AU  - Shennan,AH
AU  - Chappell,LC
DO  - 10.1016/j.preghy.2020.10.005
EP  - 47
PY  - 2021///
SN  - 2210-7789
SP  - 41
TI  - Placental growth factor measurements in the assessment of women with suspected preeclampsia: a stratified analysis of the PARROT trial
T2  - Pregnancy Hypertension
UR  - http://dx.doi.org/10.1016/j.preghy.2020.10.005
UR  - https://www.sciencedirect.com/science/article/pii/S2210778920301306?via%3Dihub
UR  - http://hdl.handle.net/10044/1/84247
VL  - 23
ER  -
Download